Age Reader

The AGE Reader provides an immediate prediction for the cardiovascular risk of your patient. The measurement is reliable, real time and non-invasive.

Moreover, the AGE Reader has been validated in clinical studies around the world. The AGE Reader has been used in clinical practice and research since 2006 in over 350 clinics worldwide. Since the introduction of the AGE Reader more than 100 peer reviewed papers have been published.

  1. The relationship between circulating irisin levels and tissues AGE accumulation in type 2 diabetes patients.
    Li Z. et al. Biosci Rep. 2017 Apr 13. doi: 10.1042/BSR20170213.
  2. Vitreous advanced glycation endproducts and α-dicarbonyls in retinal detachment patients with type 2
    diabetes mellitus and non-diabetic controls.
    Fokkens B.T. et al. PLoS One. 2017 Mar 6;12(3):e0173379. doi: 10.1371/journal.pone.0173379
  3. Diverging effects of diabetes mellitus in patients with peripheral artery disease and abdominal aortic
    aneurysm and the role of advanced glycation end-products: ARTERY study - protocol for a multicentre
    cross-sectional study.
    de Vos L.C. et al. BMJ Open. 2017 Apr 11;7(4):e012584. doi: 10.1136/bmjopen-2016-012584.
  4. A Comparative Study on Skin and Plasma Advanced Glycation End Products and Their Associations with
    Arterial Stiffness.
    Liu C.Y. et al. Pulse (Basel). 2017 Jan;4(4):208-218.
  5. Skin autofluorescence in acute kidney injury.
    Lavielle A. et al. Crit Care. 2017 Feb 9;21(1):24
  6. Lifestyle and clinical determinants of skin autofluorescence in a population-based cohort study.
    van Waateringe R. et al. Eur J Clin Invest. 2016 Mar 22. Epub.
  7. Skin autofluorescence provides additional information to the UK Prospective Diabetes Study (UKPDS) risk
    score for the estimation of cardiovascular prognosis in type 2 diabetes mellitus.
    Lutgers H. et al, Diabetologia, 2009; 52(5): 789-797